

Consolidated Financial Statements and Supplementary Information

December 31, 2024 and 2023

Table of Contents December 31, 2024 and 2023

	Page
Independent Auditors' Report	1
Consolidated Financial Statements	
Consolidated Balance Sheets	3
Consolidated Statements of Operations	5
Consolidated Statements of Changes in Net Assets	6
Consolidated Statements of Cash Flows	7
Notes to Consolidated Financial Statements	9
Supplementary Information	
Consolidating Schedule, Balance Sheet	38
Consolidating Schedule, Statement of Operations	42



Independent Auditors' Report

To the Board of Trustees of Adventist HealthCare, Inc. and Controlled Entities

Opinion

We have audited the consolidated financial statements of Adventist HealthCare, Inc. and Controlled Entities (the Corporation), which comprise the consolidated balance sheets as of December 31, 2024 and 2023, and the related consolidated statements of operations and changes in net assets and cash flows for the years then ended, and the related notes to the consolidated financial statements.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Corporation as of December 31, 2024 and 2023, and the results of their operations, changes in their net assets and their cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America (GAAP).

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the Corporation and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with GAAP, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Corporation's ability to continue as a going concern within one year after the date that the financial statements are issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Corporation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Corporation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings and certain internal control-related matters that we identified during the audit.

Supplementary Information

Our audits were conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The consolidating information as noted in the table of contents is presented for purposes of additional analysis of the consolidated financial statements rather than to present the financial position, changes in net assets and cash flows of the individual organizations, and it is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The consolidated financial statements and certain additional procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements as a certain additional procedures, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the consolidating information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Baker Tilly US, LLP

Williamsport, Pennsylvania April 25, 2025

Consolidated Balance Sheets December 31, 2024 and 2023 (In Thousands)

	 2024	2023		
Assets				
Current Assets				
Cash and cash equivalents	\$ 35,051	\$	30,207	
Short-term investments	276,816		292,515	
Assets whose use is limited	27,143		22,549	
Patient accounts receivable	131,482		137,907	
Other receivables	16,835		16,793	
Inventories	10,969		11,394	
Prepaid expenses and other current assets	 18,142		13,938	
Total current assets	516,438		525,303	
Property and Equipment, Net	855,397		805,826	
Finance Lease Right-of-Use Assets	13,874		17,940	
Operating Lease Right-of-Use Assets	84,328		92,840	
Assets Whose Use is Limited				
Under trust indentures held by trustees and banks	77,659		123,962	
Professional liability fund	11,297		12,741	
Deferred compensation fund	2,863		2,579	
Cash and Cash Equivalents Restricted for Capital Acquisitions	711		597	
Investments and Investments in Unconsolidated Subsidiaries	27,845		25,013	
Land Held for Healthcare Development	7,522		8,387	
Intangible Assets, Net	6,574		6,684	
Deposits and Other Noncurrent Assets	9,461		13,614	
Assets Held for Sale	 14,814		12,054	
Total assets	\$ 1,628,783	\$	1,647,540	

Consolidated Balance Sheets December 31, 2024 and 2023 (In Thousands)

	2024			2023		
Liabilities and Net Assets						
Current Liabilities						
Accounts payable and accrued expenses	\$	116,881	\$	130,124		
Accrued compensation and related items		59,785		54,796		
Interest payable		9,600		9,784		
Deferred revenues		7,942		8,282		
Due to third-party payors		22,220		35,038		
Estimated self-insured professional liability Current maturities of:		3,249		2,669		
Long-term obligations		16,064		21,948		
Finance lease obligations		3,878		3,814		
Operating lease obligations		12,878		12,914		
Total current liabilities		252,497		279,369		
Construction Payable		16,980		8,972		
Long-Term Obligations, Net		665,209		682,499		
Finance Lease Obligations		10,698		14,569		
Operating Lease Obligations		76,836		84,885		
Other Liabilities		14,524		15,372		
Estimated Self-Insured Professional Liability		8,572		11,825		
Total liabilities		1,045,316		1,097,491		
Net Assets						
Net assets without donor restrictions		570,486		538,843		
Net assets with donor restrictions		12,981		11,206		
		12,001		11,200		
Total net assets		583,467		550,049		
Total liabilities and net assets	\$	1,628,783	\$	1,647,540		

Consolidated Statements of Operations Years Ended December 31, 2024 and 2023 (In Thousands)

	2024	2023		
Revenues Net patient service revenue Other revenues	\$ 1,019,817 53,409	\$		
COVID-19 grant income	4,117	8,714		
Total revenues	1,077,343	1,075,575		
Expenses				
Salaries and wages	516,790	488,403		
Employee benefits	91,009	91,474		
Contract labor	54,686	86,737		
Medical supplies	122,382	122,337		
General and administrative	133,766	133,151		
Building and maintenance	55,206	59,328		
Insurance	9,747	8,150		
Interest	23,724	24,237		
Depreciation and amortization	52,617	53,000		
Total expenses	1,059,927	1,066,817		
Income from operations	17,416	8,758		
Other Income (Expense) Investment income Other loss	14,829 (9,393)	13,530 (7,999)		
Total other income	5,436	5,531		
Revenues in excess of expenses from continuing operations	22,852	14,289		
Change in Net Unrealized Gains on Investments in Debt Securities	8,634	13,763		
Net Assets Released From Restrictions for Purchases of Property and Equipment	699	6,827		
Deferred Compensation Plan Liability Adjustment	(20)	557		
Other Net Asset Activity	697	(66)		
Increase in net assets without donor restrictions from continuing operations	32,862	35,370		
Loss From Discontinued Operations	(1,219)	(2,178)		
Increase in net assets without donor restrictions	\$ 31,643	\$ 33,192		

Consolidated Statements of Changes in Net Assets Years Ended December 31, 2024 and 2023 (In Thousands)

	2024	2023		
Net Assets Without Donor Restrictions				
Revenues in excess of expenses				
from continuing operations	\$ 22,852	\$	14,289	
Change in net unrealized gains on investments				
in debt securities	8,634		13,763	
Net assets released from restrictions for purchases of				
property and equipment	699		6,827	
Deferred compensation plan liability adjustment	(20)		557	
Other net asset activity	 697		(66)	
Increase in net assets without donor				
restrictions from continuing operations	32,862		35,370	
Loss from discontinued operations	 (1,219)		(2,178)	
Increase in net assets without				
donor restrictions	 31,643		33,192	
Net Assets With Donor Restrictions				
Restricted gifts and donations	7,446		14,179	
Net assets released from restrictions for purchase of				
property and equipment	(699)		(6,827)	
Net assets released from restrictions used for operations	(4,885)		(8,248)	
Change in value of beneficial interest in trusts and charitable				
gift annuity obligation	(9)		(64)	
Change in discount of pledges receivable and provision for				
doubtful pledges	 (78)		(74)	
Increase (decrease) in net assets with donor restrictions	 1,775		(1,034)	
Increase in net assets	33,418		32,158	
Net Assets, Beginning	 550,049		517,891	
Net Assets, Ending	\$ 583,467	\$	550,049	

Consolidated Statements of Cash Flows Years Ended December 31, 2024 and 2023 (In Thousands)

	2024	 2023	
Cash Flows From Operating Activities			
Increase in net assets	\$	33,418	\$ 32,158
Adjustments to reconcile increase in net assets to net			
cash provided by operating activities:			
Depreciation and amortization		52,617	53,000
Change in operating lease right-of-use assets and obligations		15,782	20,262
Termination of operating lease right-of-use assets			
and obligations		1,144	278
Termination of finance lease right-of-use assets			
and obligations		458	469
Payments on operating lease obligations		(16,440)	(18,563)
Amortization of deferred financing costs and bond premium		(1,226)	(1,221)
Deferred compensation plan liability adjustment		20	(557)
Loss on recognition of debt guarantee on investment			. ,
in unconsolidated subsidiary		-	6,288
Loss on extinguishment of debt		-	107
Restricted contributions and grants		(7,446)	(14,179)
Gains recognized on investments in unconsolidated			
subsidiaries		(1,196)	(2,651)
Net realized and unrealized gains on investments		(4,884)	(3,866)
Change in net unrealized gains on investments			
in debt securities		(8,634)	(13,763)
Change in value of beneficial interest in trusts and charitable			
gift annuity obligation		9	64
Change in discount of pledges receivable and provision for			
doubtful pledges		78	74
Changes in assets and liabilities:			
Patient accounts receivable		6,425	(9,912)
Other receivables		(42)	31,979
Inventories, prepaid expenses and other current assets		(3,779)	(2,470)
Accounts payable and accrued expenses		(13,243)	(41,285)
Accrued compensation and related items		4,989	671
Interest payable		(184)	(143)
Deferred revenues		(340)	4,604
Estimated self-insured professional liability		(2,673)	(5,668)
Due to third-party payors		(12,818)	(28)
Other noncurrent assets and liabilities		3,308	 1,740
Net cash provided by operating activities		45,343	 37,388

Consolidated Statements of Cash Flows Years Ended December 31, 2024 and 2023 (In Thousands)

	2024			2023
Cash Flows From Investing Activities				
Purchases of property and equipment	\$	(90,143)	\$	(69,798)
Change in short-term investments, investments and				
investments in unconsolidated subsidiaries		27,277		14,601
Purchases of land held for healthcare development		(830)		(1,654)
Proceeds from the sale of land for healthcare development		1,695		2,175
Distributions from investments in unconsolidated subsidiaries		304		629
Purchase of investment in unconsolidated subsidiary		-		(2,764)
Change in assets held for sale Change in assets whose use is limited and restricted cash		(2,760) 67,841		- 69,960
Net cash provided by investing activities		3,384		
Net cash provided by investing activities		3,304		13,149
Cash Flows From Financing Activities				
Repayments on long-term obligations		(21,948)		(20,895)
Repayments of finance lease obligations		(4,295)		(4,656)
Proceeds from restricted contributions and grants		7,446		14,179
Net cash used in financing activities		(18,797)		(11,372)
Net increase in cash, cash equivalents				
and restricted cash and cash equivalents		29,930		39,165
Cash, Cash Equivalents and Restricted Cash and Cash Equivalents, Beginning		108,110		68,945
Cash, Cash Equivalents and Restricted Cash and Cash Equivalents, Ending	\$	138,040	\$	108,110
Supplemental Disclosure of Cash Flow Information Interest paid	\$	34,356	\$	31,207
Supplemental Disclosure of Noncash Investing and Financing Activities				
Operating lease obligations incurred for right-of-use asset	\$	3,952	\$	24,127
Construction payable for property and equipment	\$	16,980	\$	8,972
Recognition of debt guarantee on investment in unconsolidated subsidiaries	\$		\$	6,288
Reconciliation of Cash, Cash Equivalents and Restricted Cash and Cash Equivalents				
Cash and cash equivalents	\$	35,051	\$	30,207
Cash and cash equivalents restricted for capital acquisitions Cash and cash equivalents included in the current portion		711		597
of assets whose use is limited		27,143		22,549
Cash and cash equivalents included in the noncurrent portion of assets whose use is limited		75,135		54,757
Total cash, cash equivalents and restricted cash				
and cash equivalents	\$	138,040	\$	108,110

Notes to Consolidated Financial Statements December 31, 2024 and 2023 (In Thousands)

1. Nature of Operations and Summary of Significant Accounting Policies

Nature of Operations

Adventist HealthCare, Inc. (AHC or the Corporation) is a nonstock membership corporation organized to effectuate coordinated administration of hospitals and other health care organizations through the provision of key management and administrative services. The mission of AHC is to extend God's care through the ministry of physical, mental and spiritual healing. AHC is tax-exempt under Section 501(c)(3) of the Internal Revenue Code (IRC). AHC is not exempt from income taxes for unrelated business income. AHC's sole corporate member is Mid-Atlantic Adventist HealthCare, Inc. AHC is comprised of several operating divisions and controlled entities, as follows:

Shady Grove Medical Center (SGMC) is a 360-bed acute care hospital located in Rockville, Maryland. In addition to the acute care hospital, SGMC also has a 133-bed psychiatric hospital as part of its behavioral health and wellness services.

White Oak Medical Center (WOMC) is a 217-bed acute care hospital located in Silver Spring, Maryland.

Rehabilitation (Rehab) operates two inpatient hospitals and five outpatient locations in Maryland. The two inpatient hospitals consist of Rehab-Rockville, a 55-bed rehabilitation facility and Rehab-WOMC, a 42-bed rehabilitation facility.

Adventist HealthCare Imaging (Imaging) operates eight clinical sites and provides inpatient and outpatient imaging services at SGMC, WOMC and Adventist HealthCare Fort Washington Medical Center, Inc. (FWMC).

Adventist HealthCare Physician Enterprise (PE), formerly known as Clinical Integration Services (CIS) is comprised of Adventist Medical Group (AMG). AMG is a not-for-profit entity that provides primary care and specialty care physician professional health services to the communities it serves. The respective operating results of the specialist practices are recorded in SGMC, WOMC and FWMC. PE also includes the administration needed to facilitate the coordination of patient care across conditions, providers and settings.

The Other Health Services (OHS) operating division is comprised of two entities. Lifework Strategies (LWS) provides employee assistance and employee wellness programs to client employees. LWS's mission is to help individuals live healthier, happier and more productive lives. Capital Choice Pathology Lab (CCPL) provides full pathology production services to client hospitals.

In May 2020, AHC opened a 200-bed alternate care site (ACS) on the Takoma Park campus to increase the number of beds available in the State of Maryland to care for patients as a result of the COVID-19 pandemic. This was approved by the Maryland Health Care Commission and in accordance with the terms of the agreement with the State of Maryland, all costs to open, operate, close and decommission the campus were reimbursed.

Notes to Consolidated Financial Statements December 31, 2024 and 2023 (In Thousands)

AHC has amounts due from the State of Maryland of \$110 as of December 31, 2023 which is included in other receivables in the accompanying consolidated balance sheets. There were no amounts due from the State of Maryland as of December 31, 2024. Any reimbursement received by the Corporation for services provided to patients is required to be remitted to the State of Maryland. The Corporation has amounts due to the State of Maryland of \$1,100 as of December 31, 2023, which is included in accounts payable and accrued expenses in the accompanying consolidated balance sheets. There were no amounts due to the State of Maryland as of December 31, 2024. The agreement ended in April 2023. The termination of the State of Emergency and a Catastrophic Health Emergency proclamation by the Governor of Maryland occurred in May 2023. The financial results of the ACS are included in OHS.

The Support Center is comprised of the Corporate Office (CO) and the AHC benefit business unit. The CO provides corporate and centralized shared service functions that benefit the entire AHC system. The AHC benefit business unit administers the self-insurance health benefit program, including health insurance, dental and vision coverage for AHC and controlled entities.

Philanthropy (formerly known as the Foundation) is an operating division of the Corporation that operates for the furtherance of the Corporation's health care objectives primarily through the solicitation of contributions, gifts and bequests. Philanthropy also exists to help fund new equipment purchases and capital improvement projects. In 2024, the operations from the existing foundations were combined into one new entity under control by the Corporation. All of the Foundation's assets were moved to the parent company of the Corporation and Philanthropy continues to support the Corporation's mission and objectives.

FWMC is a 33-bed acute care hospital located in Fort Washington, Maryland.

The Lourie Center for Infants and Young Children (Lourie Center) is a not-for-profit organization that specializes in the diagnosis, treatment and prevention of developmental and emotional disorders in children from birth through 10 years of age.

Adventist Home Care Services, Inc. (AHCS) is a nonstock membership corporation organized to provide home health services in Maryland and includes Adventist Home Assistance (AHA). AHA provides nonclinical assistance to homebound patients who cannot perform certain daily activities on their own.

Other Leasehold Services (formerly known as Adventist HealthCare Urgent Care Center, Inc. (Urgent Care)) was comprised of three urgent care centers located in Germantown, Laurel and Rockville, Maryland. AHC sold and entered into an affiliation agreement with an unrelated party as of February 1, 2022 to become the exclusive health system affiliate for the urgent care centers through One Health Quality Alliance (OHQA). AHC continues to lease certain locations to the unrelated party. AHC dissolved the Urgent Care entity as of January 2025.

The Adventist HealthCare Physician Alliance (HPA) (formerly known as OHQA) is a physician-led clinically integrated network designed to deliver value to payors, employers and consumers through the highest quality care at a lower cost. Through this alliance, participating physicians gain access to resources to support the transition to value-based care, while maintaining their independence. Through this collaboration, HPA aims to improve the health of patient populations and communities, while enhancing the patient experience and reducing the costs of health care. HPA currently has over 2,200 physician members, most of whom are on the medical staff of AHC, including primary care, orthopedics and other community and hospital-based specialists.

All of the operating divisions and controlled entities mentioned above are tax-exempt under Section 501(c)(3) of the IRC.

Principles of Consolidation

The consolidated financial statements include the accounts of AHC, the controlling parent, SGMC, WOMC, Rehab, Imaging, PE, LWS, CCPL, the Support Center, Philanthropy, FWMC, the Lourie Center, AHCS, Other Leasehold Services, HPA, which include their majority-owned subsidiaries and controlled affiliates (collectively, the Corporation). All significant intercompany balances and transactions have been eliminated in the consolidated financial statements of the Corporation.

Reclassification

Certain 2023 amounts have been reclassified to conform to the 2024 consolidated financial statements presentation.

Subsequent Events

The Corporation evaluated subsequent events for recognition or disclosure through April 25, 2025, the date the consolidated financial statements were issued.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Maryland Health Services Cost Review Commission

Certain hospital charges are subject to review and approval by the Maryland Health Services Cost Review Commission (HSCRC). The HSCRC has jurisdiction over hospital reimbursement in Maryland by agreement with the Centers for Medicare and Medicaid Services (CMS). This agreement is based on a waiver from the Medicare Prospective Payment System reimbursement principles granted under Section 1814(b) of the Social Security Act. Management has filed the required forms with the HSCRC and believes all entities that fall under the HSCRC's jurisdiction comply with applicable requirements.

In January 2014, CMS approved a modernized waiver that grants Maryland (via the HSCRC) the authority to regulate hospital revenue within a rigorous annual expenditure limit. Maryland's Total Cost of Care Agreement builds on decades of innovation and equity in healthcare payment and delivery - with an aim to enhance patient care, improve health outcomes and lower costs.

As a result of the waiver, the HSCRC introduced revenue arrangements, including the Global Budget Revenue (GBR) model. The GBR methodology encourages hospitals to focus on population health strategies by establishing a fixed annual revenue cap for each GBR hospital. The agreement establishes a fixed amount of charging authority (i.e., revenue) at the beginning of the rate year. It is evergreen in nature and covers both regulated inpatient and outpatient revenues. Revenue is calculated from a base year and is adjusted annually for inflation, infrastructure requirements, population changes, performance in quality-based programs and changes in the levels of uncompensated care. Revenue may also be adjusted annually for market levels and shifts of services from one health system to another and from a regulated setting to an unregulated setting (or vice versa).

Notes to Consolidated Financial Statements December 31, 2024 and 2023 (In Thousands)

In 2014, AHC entered into GBR Agreements with the HSCRC for SGMC, WOMC and Shady Grove Germantown Emergency Center. FWMC also entered into a GBR agreement with the HSCRC in 2014 - prior to its affiliation with AHC. The agreements set an initial fixed amount of revenue for each entity for the period July 1, 2013 through June 30, 2014, and they have been subsequently updated on an annual basis every July 1 since that time.

The HSCRC requires rate-regulated hospitals under its jurisdiction to calculate the amount of patient charges that are less than or in excess of their approved global revenue base. To the extent that the patient charges differ from the approved global revenue base, these price variances are removed from (in an overcharge situation) or added to (in an undercharge situation) the hospital's rate order in the subsequent year. Because these price variances from approved revenue cannot be retained, it is the Corporation's policy to adjust net patient revenue equal to the amount of the price variances. The Corporation reported net overcharges of \$15,091 and \$13,192 as of December 31, 2024 and 2023, respectively. These price variances reflect the variance between actual patient charges and the pro-rata share of approved rate orders (adjusted for certain revenue adjustments expected to be made in a future period). The net amounts are reported as a component of net patient service revenue and patient accounts receivable in the accompanying consolidated financial statements. Since the HSCRC's rate year extends from July 1 through June 30, these amounts will continue to fluctuate until the end of the rate year as actual patient charges deviate from the total approved charging authority. At the conclusion of each rate year (June 30), the value of any overcharge liability (or undercharge asset) is amortized on the straight-line basis over the following rate year when the price variance adjustments are actually built into each entity's rate order.

Under Maryland law, charges of specialty hospitals such as Rehab are subject to review and approval by the HSCRC. The HSCRC regulations also include a provision whereby a hospital may apply for an exemption from the requirements to charge for services in accordance with the HSCRC regulations. Certain conditions regarding the percentage of revenue related to Medicare and Medicaid patients must be met to receive the initial exemption, and those same conditions, must be met each year thereafter. Reporting requirements as established by the HSCRC continue even if an exemption regarding charging for services is received. The Corporation's management believes Rehab met the conditions for exemption during 2024 and 2023.

In November 2023, CMS rolled out the All-Payer Health Equity Approaches and Development (AHEAD) model for healthcare to serve as a blueprint for improving population health, advancing health equity and controlling healthcare costs. The model is a comprehensive framework designed to incentivize states to implement broad changes in delivering and paying for healthcare. Maryland is one of the states that have applied for inclusion in the Model framework, and it now serves as the vehicle through which the waiver from the Medicare Prospective Payment System reimbursement principles is secured.

The guiding principles under the AHEAD Model are familiar to healthcare providers in Maryland because the key features in the model are consistent with the types of programs Maryland has been pursuing since 2014. These key features include (1) assuming responsibility for managing all healthcare costs within the state's borders (not just those specific to programs like Medicare and Medicaid), (2) strengthening the availability of (and access to) primary care, (3) developing specific plans to address health disparities and improve health outcomes for underserved populations and (4) a reimbursement model that holds hospitals to operate within the constraint of global revenue budgets.

Maryland has already committed itself to operate under the principles and requirements of the AHEAD model. As such, a Participation Agreement has already been executed between CMS and the State. However, many of the statewide accountability targets with respect to savings, primary care investment, limits on revenue growth, etc. are still being developed.

Cash and Cash Equivalents

Cash and cash equivalents include investments in money market funds and certificates of deposit purchased with original maturities of less than 90 days, excluding assets whose use is limited. For purposes of the consolidated statements of cash flows, cash, cash equivalents and restricted cash and cash equivalents include investments purchased with an initial maturity of three months or less.

Patient Accounts Receivable

The Corporation assesses collectability on patient contracts prior to the recognition of net patient service revenue. Patient accounts receivable are reported at their net realizable value. Accounts are written off through the credit loss expense when the Corporation has exhausted all collection efforts and determines accounts are impaired based on changes in patient credit worthiness. Patient accounts receivable also includes management's estimate of the impact of certain undercharges to be recouped or overcharges to be paid back for inpatient and outpatient services in subsequent years rates as discussed earlier.

Other Receivables

Other receivables represent amounts due to the Corporation for charges other than providing health care services to patients, and pledges from donors reported at their net realizable value. These services include, but are not limited to, fees from educational programs, rental of health care facility space, interest earned and management services. Other receivables are written off when they are determined to be uncollectible based on management's assessment of individual accounts.

Assets Whose Use Is Limited

Assets whose use is limited includes assets held by bond trustees under trust indentures, assets set aside as required by the Corporation's self-funded professional liability fund, and assets set aside for deferred compensation agreements. Amounts available to meet current liabilities of the Corporation have been reclassified as current assets in the accompanying consolidated balance sheets.

Investments and Investment Risk

Investments in equity securities with readily determinable fair values and all investments in debt securities are measured at fair value in the accompanying consolidated balance sheets. Cash and cash equivalents and certificates of deposit are carried at cost which approximates fair value. The Corporation has alternative investments that represent ownership interests in managed funds. The alternative investments are stated at fair value based on the Corporation's percentage of the net asset value (NAV) of the funds and represents a practical expedient of fair value.

Investment income or loss (including realized and unrealized gains and losses on investments, writedowns of the cost basis of investments in debt securities due to an other-than-temporary decline in fair value, interest and dividends) is included in the determination of revenues in excess of expenses from continuing operations unless the income or loss is restricted by donor or law. Unrealized gains and losses on investments in debt securities are excluded from the determination of revenues in excess of expenses from continuing operations. Donor restricted investment income is reported as an increase in net assets with donor restrictions. Investments available for current operations have been classified as short-term investments in the accompanying consolidated balance sheets.

Investments and investments in unconsolidated subsidiaries includes the Corporation's investments in healthcare entities in which the Corporation has a financial interest. The Corporation follows authoritative guidance in determining whether to record such investments using the equity method.

The Corporation's investments are comprised of a variety of financial instruments. The fair values reported in the consolidated balance sheets are subject to various risks, including changes in the equity markets, the interest rate environment and general economic conditions. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the fair value of investment securities, it is reasonably possible that the amounts reported in the accompanying consolidated financial statements could change materially in the near term.

Inventories

Inventories of drugs, medical supplies and surgical supplies are valued at the lower of cost or net realizable value. Cost is determined primarily by the weighted average cost method.

Property and Equipment, Net

Property and equipment acquisitions are recorded at cost. Depreciation is provided over the estimated useful lives of the assets using the straight-line method.

Gifts of long-lived assets such as land, buildings or equipment are reported as unrestricted support unless explicit donor stipulations specify how the donated assets must be used. Gifts of long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are reported as restricted support. Expirations of donor restrictions are reported when the donated or acquired long-lived assets are placed in service.

Impairment losses are recognized in the consolidated statements of operations as a component of revenues in excess of expenses from continuing operations as they are determined. The Corporation reviews its long-lived assets whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In that event, the Corporation calculates the estimated future net cash flows to be generated by the asset. If those future net cash flows are less than the carrying value of the asset, an impairment loss is recognized for the difference between the estimated fair value and the carrying value of the asset. There were no impairment losses on property and equipment recognized in 2024 or 2023.

Leases and Right-of-Use Assets

The Corporation evaluates at contract inception whether a lease exists and recognizes a lease obligation and right-of-use (ROU) asset for all leases with a term greater than 12 months. Leases are classified as either finance or operating. All lease liabilities are measured as the present value of the future lease payments using a discount rate. The future lease payments used to measure the lease liability include fixed payments, as well as the exercise price of any options to purchase the underlying asset that have been deemed reasonably certain of being exercised, if applicable. Future lease payments for optional renewal periods that are not reasonably certain of being exercised are excluded from the measurement of the lease liability. For all leases, the ROU asset is initially derived from the measurement of the lease liability and adjusted for certain items, such as initial direct costs and lease incentives received. ROU assets are subject to long-lived impairment testing.

Amortization of finance lease ROU assets, which is recognized on a straight-line basis over the lesser of the lease term or the estimated useful life of the asset, is included within depreciation and amortization expense in the consolidated statements of operations. Interest expense associated with finance lease obligations is included within interest expense in the consolidated statements of operations.

Operating lease expense is recognized on a straight-line basis over the lease term and is included within building and maintenance expense in the consolidated statements of operations. The lease term is determined based on the date the Corporation acquires control of the leased premises or equipment through the end of the lease term. Optional renewal periods are initially not included in the lease term unless they are deemed to be reasonably certain of being exercised at lease commencement.

Intangible Assets

The Corporation's intangible assets primarily include costs in excess of net assets acquired related to certain business acquisitions. The Corporation is amortizing certain intangible assets over a period not to exceed 40 years. Amortization of these intangible assets was \$110 in 2024 and \$641 in 2023. Accumulated amortization of intangible assets was \$5,402 and \$5,292 as of December 31, 2024 and 2023, respectively.

Goodwill, which is included in intangible assets in the accompanying consolidated balance sheets, is reviewed annually for impairment or more frequently if events or circumstances indicate the carrying amount of the goodwill will not be recoverable. There were no impairment losses recognized on goodwill in 2024 or 2023.

Deferred Financing Costs

Costs incurred in connection with the issuance of long-term obligations have been deferred and are being amortized over the term of the related obligation using the straight-line method. Deferred financing costs remaining as of December 31, 2024 and 2023 totaled \$5,076 and \$5,363, respectively, and are included in the consolidated balance sheets as a reduction of bonds payable, which is included in long-term obligations on the consolidated balance sheets. Amortization expense was \$287 and \$293 in 2024 and 2023, respectively, and is included as a component of interest expense in the consolidated statements of operations.

Due to Third-Party Payors

The Corporation receives advances from third-party payors to provide working capital for services rendered to the beneficiaries of such services. These advances are principally determined based on the timing differences between the provision of care and the anticipated payment date of the claim for service in accordance with the HSCRC's rate regulations. These advances are subject to periodic adjustment and are intended to provide adequate funding to providers while they wait for the final adjudication of claims issued to each payer. These working capital advances are reported as a current liability in the consolidated balance sheets.

For those services that are subject to a cost settlement with third-party payors, the Corporation evaluates estimated reimbursable cost, the terms of the payment agreement with the payor, correspondence with the payor, and the Corporation's historical settlement activity to determine if an adjustment to the interim payment rate should be recorded in the underlying consolidated statements of operations. A key point of this evaluation provides consideration to retroactive adjustments (or expected adjustments) due to audits, reviews or investigations. Any changes in settlement estimates are recognized as a component of income in the period such a determination is made. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information become available), or as years are settled or no longer subject to such audits, reviews, and investigations. Adjustments arising from these cost settlement processes were not significant in 2024 or 2023.

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result, health care entities may, from time to time and in the ordinary course of business, receive requests for information and notices from government agencies regarding alleged noncompliance with those laws and regulations, some of which may result in settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties and potential exclusion from the related programs. Management is not aware of any material incidents of noncompliance; however, there can be no assurance that regulatory authorities will not challenge the Corporation's compliance in the future.

Estimated Self-Insured Professional Liability

The provision for estimated self-insured professional liability includes estimates of the ultimate costs for both reported claims and claims incurred but not reported, including costs associated with litigating or settling claims. Anticipated insurance recoveries associated with reported claims, if any, are recognized in the Corporation's consolidated balance sheets at net realizable value.

Net Assets

Net assets, revenues, gains and losses are classified based on the existence or absence of donor imposed restrictions. Accordingly, net assets and changes therein are classified and reported as follows:

Net Assets Without Donor Restrictions - Net assets without donor restrictions include amounts available for use in general operations and not subject to donor restrictions. All revenues not restricted by donors as well as donor restricted contributions whose restrictions are met in the same period in which they are received, are accounted for in net assets without donor restrictions.

Net Assets With Donor Restrictions - Net assets with donor restrictions include amounts subjected to donor imposed restrictions which are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other donor-imposed restrictions are perpetual in nature, where the donor stipulates that resources be maintained in perpetuity. All revenues restricted by donors as to either timing or purpose of the related expenditures or required to be maintained in perpetuity as a source of investment income are accounted for in net assets with donor restrictions. When a donor restriction expires, that is when a stipulated time restriction ends or purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions. Net assets were released from donor restriction by satisfying their restricted purposes in the amount of \$5,584 in 2024 and \$15,075 in 2023.

Net assets with donor restrictions includes those whose use by the Corporation has been limited by donors to specific purposes in the amount of \$12,981 and \$11,206 as of December 31, 2024 and 2023, respectively.

Unconditional promises to give cash and other assets are reported at fair value at the date the promise is received. Conditional promises to give and indications of intentions to give are reported at fair value at the date the gift is received or when the underlying conditions have been substantially met. The gifts are reported as net assets with donor restrictions if they are received with donor stipulations that limit the use of the donated assets. Restricted funds to be used for capital acquisitions have been reported as noncurrent assets in the accompanying consolidated balance sheets, while other restricted cash and investments are included with the cash and cash equivalents of net assets without donor restrictions.

Measure of Operations

The consolidated statements of operations reflect all changes in net assets without donor restrictions, including changes from both operating and nonoperating activities. Operating revenues and expenses consist of those items that are an integral part of the Corporation's provision of healthcare and related supporting activities. Nonoperating activities are limited to resources that generate return from investments and other activities considered to be of a more unusual or nonrecurring nature.

Revenues in Excess of Expenses From Continuing Operations

The consolidated statements of operations include the determination of revenues in excess of expenses from continuing operations. Revenues in excess of expenses from continuing operations is the Corporation's performance indicator. Changes in net assets without donor restrictions which are excluded from the determination of revenues in excess of expenses from continuing operations, consistent with industry practice, include the change in net unrealized gains and losses on investments in debt securities, contributions of long-lived assets (including contributions which by donor restriction were to be used for the purpose of acquiring such long-lived assets), the deferred compensation plan liability adjustment, other net asset without donor restriction activity, and the loss from discontinued operations.

Net Patient Service Revenue

Net patient service revenue is recognized at the amount that reflects the consideration to which the Corporation expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payors (including commercial and governmental programs) and others and includes variable consideration for retroactive revenue adjustments due to settlement of audits, reviews and investigations. Generally, the Corporation bills the patients and third-party payors after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by the Corporation. Revenues for performance obligations satisfied over time are recognized based on actual charges incurred in relation to total expected (or actual) charges, ultimately adjusted in accordance with the charging authority awarded at the beginning of every year by the HSCRC. The Corporation believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in our hospitals receiving services over multiple days. The Corporation measures the performance obligation from admission into the hospital to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. Revenues for performance obligations satisfied at a point in time are generally recognized when goods or services are provided and the Corporation does not believe it is required to provide additional services to the patient. Generally, performance obligations satisfied at a point in time relate to patients receiving outpatient services in a single day. The Corporation measures the performance obligation from the commencement of the outpatient service, to the point when it is no longer required to provide services to that patient, which is generally the completion of the outpatient service.

All of the Corporation's performance obligations generally relate to contracts with a duration of less than one year. Therefore, the Corporation has elected to apply the optional exemptions provided in the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 606-10-50-14(a) and as a result is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

Notes to Consolidated Financial Statements December 31, 2024 and 2023 (In Thousands)

The Corporation determines the transaction price based on standard charges for services provided, reduced by contractual adjustments provided to third-party payors, financial assistance provided to uninsured or underinsured patients in accordance with the Corporation's policies, and/or implicit price concessions provided to uninsured or underinsured patients. The Corporation determines its estimates of contractual adjustments based on contractual agreements, its financial assistance policies and historical experience. The Corporation determines its estimates of implicit price concessions based on its historical collection experience with a respective class of patient. The Corporation pursues collection of amounts defined as implicit price concessions.

The Corporation has elected the practical expedient allowed under FASB ASC 606-10-32-18 and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the Corporation's expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less.

COVID-19 Grant Income and Deferred Revenues

COVID-19 grant income includes amounts received from federal, state and local funding sources related to the COVID-19 pandemic. The Corporation accounts for this funding in accordance with the FASB ASC 958-605 guidance for conditional contributions, and accordingly, revenues are measured and recognized when barriers are substantially met, which occurs when the Corporation complies with the terms and conditions related to the purpose of the grant, rather than those that are administrative in nature.

FEMA obligated \$4,117 and \$4,711 for eligible costs in the years ended December 31, 2024 and 2023, respectively. All amounts obligated by FEMA in the years ended December 31, 2024 and 2023 have been received and no amounts remain outstanding as of December 31, 2024.

The Corporation also received funding from various state and other funding sources of \$4,003 in 2023 to offset eligible expenses in accordance with the terms and conditions of the respective funding sources.

The Corporation incurred eligible expenses of \$8,714 in 2023 in accordance with the terms of the respective funding sources. These amounts were recognized and included in COVID-19 grant income in the accompanying consolidated statements of operations.

The majority of the funding received is subject to future reporting and audit requirements. Noncompliance with the terms and conditions of the funding sources could result in repayment of some or all of the support, which can be subject to government review and interpretation. An estimate of the possible effects of these matters cannot be made as of the date these consolidated financial statements were issued.

Income Taxes

The Corporation accounts for uncertainty in income taxes using a recognition threshold of more-likely-than-not to be sustained upon examination by the appropriate taxing authority. Measurement of the tax uncertainty occurs if the recognition threshold is met. Management determined there were no tax uncertainties that met the recognition threshold in 2024 or 2023.

The Corporation's policy is to recognize interest related to unrecognized tax benefits and penalties in interest expense in operating expenses.

Charity Care

The Corporation provides care to patients who meet certain criteria under its charity care policy without charge or at amounts less than its established rates. Such patients are identified based on financial information obtained from the patient (or their guarantor) and subsequent analysis which includes the patient's ability to pay for services rendered. Because the Corporation does not pursue collection of amounts determined to qualify as charity care, such amounts are not reported as a component of net patient service revenue or patient accounts receivable.

The Corporation maintains records to identify and monitor the level of charity care it provides. The costs associated with the charity care services provided are estimated by applying a cost-to-charge ratio to the amount of gross uncompensated charges for the patients receiving charity care. The level of charity care provided by the Corporation amounted to \$17,291 and \$21,298 in 2024 and 2023, respectively.

Advertising Costs

The Corporation expenses advertising costs as they are incurred.

2. Discontinued Operations and Assets Held for Sale

The Corporation made the decision to relocate Washington Adventist Hospital to White Oak, as a result of limited opportunities for growth and expansion on the Takoma Park campus. The new campus was considered a better way for the Corporation to expand access to care throughout the Washington, D.C. region, leading to the decision to sell the campus. In July 2019, AHC entered into an agreement to sell the Takoma Park campus to an unrelated third-party. The closing of the sale was delayed due to the use of the Takoma Park campus for the ACS (see Note 1). The ACS closed in April 2023 and discussions are underway to update the terms of the sales agreement, given the passage of time. The outcome of these negotiations will determine the timing of the closing for the sale of the Takoma Park campus.

The Corporation also incurred other miscellaneous operating expenses related to the maintenance of the Takoma Park Campus. The expenses are included in the loss from discontinued operations in the accompanying consolidated statements of operations in 2024 and 2023. The loss on discontinued operations was \$1,219 and \$2,178 for the years ended December 31, 2024 and 2023, respectively.

Assets held for sale in the accompanying consolidated balance sheets is comprised of land and improvements and building and improvements totaling \$14,814 and \$12,054 at December 31, 2024 and 2023, respectively, that will be sold as part of the agreement. No gain or loss on sale has been recognized in 2024 or 2023.

3. Net Patient Service Revenue

The Corporation routinely obtains assignments of (or is otherwise entitled to receive) patient benefits receivable under their health insurance programs, plans or policies (i.e. third-party payors). Third-party payors include both government payors, which include Medicare, Medicaid and Managed Care Organizations and commercial insurance carriers. Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of payment arrangements with third-party payors, by service type, is as follows:

- Global Budget Revenue SGMC, WOMC and FWMC have entered into agreements by which the third-party payors pay a percentage of approved HSCRC charges. A reduced percentage can be obtained if the payor advances a certain amount of working capital.
- Rehabilitation services Rehab has entered into agreements by which the third-party payors pay at a contract rate per day or visit.

Notes to Consolidated Financial Statements December 31, 2024 and 2023 (In Thousands)

- Physician practice services AMG has entered into agreements by which the third-party payors pay negotiated rates per procedure as defined in the term sheet of the agreements.
- Imaging services Imaging has entered into agreements by which the third-party payors pay negotiated rates per procedure as defined in the term sheet of the agreements.
- Home health services AHCS has entered into agreements by which the third-party payors pay negotiated rates on a per visit basis.

Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. The Corporation also provides services to uninsured patients, and offers those uninsured or underinsured patients financial assistance, by either policy or law, from standard charges. The Corporation estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charges by any contractual adjustments, financial assistance and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to net patient service revenue in the period of the change. Subsequent changes that are determined to be the result of an adverse change in the patient's ability to pay are recorded as credit loss expense.

Consistent with the Corporation's mission, care is provided to patients regardless of their ability to pay. Therefore, the Corporation has determined it has provided implicit price concessions to uninsured patients and other patient balances (for example, copays and deductibles). The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts the Corporation expects to collect based on its collection history with those patients.

The Corporation disaggregates revenue from contracts with customers by type of service and payor source as this depicts the nature, amount, timing and uncertainty of its revenues and cash flows as affected by economic factors. Tables providing details of these factors are presented below.

Net patient service revenue disaggregated by service type for the years ended December 31, 2024 and 2023 are as follows:

	 2024	2023		
Global budget revenue	\$ 839,725	\$	815,722	
Rehabilitation services	73,767		67,348	
Physician practice services	43,319		39,871	
Imaging services	35,704		32,966	
Home health services	25,450		23,445	
Other health services	 1,852		3,445	
Total	\$ 1,019,817	\$	982,797	

Net patient service revenue disaggregated by payor for the years ended December 31, 2024 and 2023 are as follows:

	N	ledicare	N	ledicaid	-	ther Third rty Payors	Self-Pay nd Other	 Total
December 31, 2024	\$	352,777	\$	70,528	\$	563,044	\$ 33,468	\$ 1,019,817
December 31, 2023	\$	338,172	\$	87,382	\$	526,675	\$ 30,568	\$ 982,797

Notes to Consolidated Financial Statements December 31, 2024 and 2023 (In Thousands)

Contract Balances

Contract assets represent the Corporation's right to consideration in exchange for goods or services that the Corporation has transferred to a patient when that right is conditioned on something other than the passage of time (for example, the Corporation's future performance). Contract liabilities represent the Corporation's obligation to transfer goods or services to a patient for which the Corporation has received consideration (or the amount is due) from the patient.

The Corporation's beginning and ending contract assets and liabilities are separately presented on the consolidated balance sheets as of December 31, 2024 and 2023. Contract assets of patient accounts receivable as of December 31, 2022 were \$127,995 and contract liabilities of amounts due to third party payors as of December 31, 2022 were \$35,066.

4. Investments

Short-Term Investments

The Corporation's short-term investments at December 31, 2024 and 2023 are comprised of the following:

	2024			2023
Cash and cash equivalents	\$	1,635	\$	8,435
Corporate bonds		72,344		75,247
Asset backed securities		77,181		92,522
Marketable equity securities		29,966		25,111
U.S. government securities,				
U.S. treasury notes		52,789		53,075
Mutual funds:				
Equity, balanced		6,229		5,936
Equity, growth		5,943		5,871
Alternative investments		30,729		26,318
Total short-term investments	\$	276,816	\$	292,515

Assets Whose Use is Limited

The composition of assets whose use is limited at December 31, 2024 and 2023 is set forth in the following tables:

	2024			2023
Under trust indentures held by trustees and banks: Cash and cash equivalents U.S. government securities:	\$	100,530	\$	76,403
U.S. treasury notes U.S. government agency notes		- 1,023		56,234 11,205
Total		101,553		143,842
Less funds held for current liabilities		(23,894)		(19,880)
Noncurrent portion of assets held under trust indentures held by trustees and banks	\$	77,659	\$	123,962

Notes to Consolidated Financial Statements December 31, 2024 and 2023 (In Thousands)

	:	2024	2023		
Professional liability fund:					
Cash and cash equivalents Mutual funds:	\$	1,748	\$	903	
Equity, large value		2,072		2,932	
Equity, growth		3,480		2,878	
Fixed income, intermediate		2,161		3,461	
Fixed income, multi-sector		3,467		2,651	
Fixed income, short-term		1,618		2,585	
Total		14,546		15,410	
Less funds held for current liabilities		(3,249)		(2,669)	
Noncurrent portion of professional liability fund	\$	11,297	\$	12,741	
Deferred compensation fund:					
Mutual funds:					
Equity, growth	\$	30	\$	45	
Equity, large value		378		653	
Equity, midcap value		37		188	
Equity, other		2,185		517 366	
Equity, international Fixed income, multi-sector		77 46		300 227	
Fixed income, intermediate		110		583	
Noncurrent portion of deferred compensation fund	\$	2,863	\$	2,579	

The indenture requirements of certain tax-exempt financings provide for the establishment and maintenance of various accounts with a trustee (Note 10). These arrangements require the trustee to control the payment of interest and the ultimate repayment of respective debt to bondholders.

The composition of assets whose use is limited under trust indentures held by trustees and banks at December 31, 2024 and 2023 is as follows:

	 2024	2023		
Debt service reserve funds Principal and interest funds Project fund	\$ 26,085 24,559 50,909	\$	25,624 25,330 92,888	
Total	\$ 101,553	\$	143,842	

Notes to Consolidated Financial Statements December 31, 2024 and 2023 (In Thousands)

Investment income and gains and losses for investments, assets whose use is limited and cash and cash equivalents without donor restrictions are comprised of the following in 2024 and 2023:

	 2024	2023		
Investment income:				
Interest and dividends, net	\$ 9,146	\$	8,872	
Interest on trustee held funds Net realized and unrealized gains	799		792	
on investments	 4,884		3,866	
Total	\$ 14,829	\$	13,530	
Other changes in net assets without donor restrictions: Change in net unrealized gains on investments in debt				
securities	\$ 8,634	\$	13,763	

5. Fair Value Measurements and Financial Instruments

The Corporation measures its short-term investments, assets whose use is limited, investments and beneficial interest in trusts at fair value on a recurring basis in accordance with accounting principles generally accepted in the United States of America.

Fair value is defined as the price that would be received to sell an asset or the price that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The framework that the authoritative guidance establishes for measuring fair value includes a hierarchy used to classify the inputs used in measuring fair value. The hierarchy prioritizes the inputs used in determining valuations into three levels. The level in the fair value hierarchy within which the fair value measurement falls is determined based on the lowest level input that is significant to the fair value measurement.

The levels of the fair value hierarchy are as follows:

Level 1 - Fair value is based on unadjusted quoted prices in active markets that are accessible to the Corporation for identical assets. These generally provide the most reliable evidence and are used to measure fair value whenever available.

Level 2 - Fair value is based on significant inputs, other than Level 1 inputs, that are observable either directly or indirectly for substantially the full term of the asset through corroboration with observable market data. Level 2 inputs include quoted market prices in active markets for similar assets, quoted market prices in markets that are not active for identical or similar assets and other observable inputs.

Level 3 - Fair value would be based on significant unobservable inputs. Examples of valuation methodologies that would result in Level 3 classification include option pricing models, discounted cash flows and other similar techniques.

Notes to Consolidated Financial Statements December 31, 2024 and 2023 (In Thousands)

The fair value of the Corporation's financial instruments was measured using the following inputs at December 31:

	2024							
	Fair Value		Acti	ed Prices in ve Markets Level 1)	Other Observable Inputs (Level 2)		Inp	ervable outs /el 3)
Reported at Fair Value								
Assets:								
Mutual funds:								
Fixed income,								
intermediate	\$	2,271	\$	2,271	\$	-	\$	-
Fixed income, multi-sector		3,513		3,513		-		-
Fixed income, short-term		1,618		1,618		-		-
Equity, international		77		77		-		-
Equity, growth		9,453		9,453		-		-
Equity, large value		2,450		2,450		-		-
Equity, balanced		6,229		6,229		-		-
Equity, midcap value		37		37		-		-
Equity, other		2,185 29,966		2,185		-		-
Marketable equity securities U.S. government securities:		29,900		29,966		-		-
U.S. treasury notes		52,789		_		52,789		_
U.S. government notes		1,023				1,023		
Asset backed securities		77,181		_		77,181		_
Corporate bonds		72,344		-		72,344		-
Total assets measured								
at fair value		261,136	\$	57,799	\$	203,337	\$	-
Cash and cash equivalents Alternative investments		104,883						
measured at net asset value		30,729						
Total	\$	396,748						

Notes to Consolidated Financial Statements December 31, 2024 and 2023 (In Thousands)

	2023							
				ed Prices in ve Markets .evel 1)		Other oservable Inputs Level 2)	In	servable puts vel 3)
Reported at Fair Value								
Assets:								
Mutual funds:								
Fixed income,								
intermediate	\$	4,044	\$	4,044	\$	-	\$	-
Fixed income, multi-sector		2,878		2,878		-		-
Fixed income, short-term		2,585		2,585		-		-
Equity, international		366		366		-		-
Equity, growth		8,794		8,794		-		-
Equity, large value		3,585		3,585		-		-
Equity, balanced		5,936		5,936		-		-
Equity, midcap value		188		188		-		-
Equity, other		517		517		-		-
Marketable equity securities		25,111		25,111		-		-
U.S. government securities:								
U.S. treasury notes		109,309		-		109,309		-
U.S. government notes		11,205		-		11,205		-
Asset backed securities		92,522		-		92,522		-
Corporate bonds		75,247		-		75,247		-
Beneficial interest in trusts		165		-		-		165
Total assets measured								
at fair value		342,452	\$	54,004	\$	288,283	\$	165
Cash and cash equivalents Alternative investments		86,665						
measured at net asset value		26,318						
Total	\$	455,435						

The following represents a reconciliation of the assets reported at fair value included in the fair value table within the accompanying consolidated balance sheets at December 31:

	 2024	2023		
Short-term investments (Note 4) Assets whose use is limited (Note 4):	\$ 276,816	\$	292,515	
Current portion	27,143		22,549	
Under trust indentures held by trustees and banks	77,659		123,962	
Professional liability fund	11,297		12,741	
Deferred compensation fund	2,863		2,579	
Investments held by philanthropy, included in deposits and other noncurrent assets and investments and investments in unconsolidated subsidiaries	970		924	
Beneficial interest in trusts, included in deposits and other noncurrent assets	 <u> </u>		165	
	\$ 396,748	\$	455,435	

Notes to Consolidated Financial Statements December 31, 2024 and 2023 (In Thousands)

The following is a description of the valuation methodologies used for assets and liabilities measured at fair value. There have been no changes in methodologies used at December 31, 2024 and 2023.

Mutual funds and marketable equity securities are valued based on quoted market prices.

U.S. government securities, asset backed securities and corporate bonds are valued based on estimated quoted market prices of similar securities.

Beneficial interest in trusts are valued based on the fair value of the trusts underlying assets which represents a proxy for discounted present value of future cash flows.

The Corporation has alternative investments in Blackstone Real Estate Income Trust (Blackstone), Blackstone Private Credit Fund (Blackstone PC) and Ares Real Estate income Trust, Inc. (Ares) (collectively, the Funds). The Funds are valued based on the NAV per share of the fund which is based on the fair value of their underlying assets derived principally from or corroborated by observable market data by correlation or other means. There are no unfunded purchase commitments for the Funds as of December 31, 2024. The value of the Funds is as follows as of December 31:

	2024			2023		
Blackstone Blackstone PC	\$	8,062 15,104	\$	7,918 10,645		
Ares		7,563		7,755		
Total	\$	30,729	\$	26,318		

The following represents the investment strategies and share redemption policies for each fund:

Blackstone: The investment strategy for this fund is to acquire primarily stabilized, incomegenerating commercial real estate across asset classes in the United States and outside the United States, as well as in real estate debt investments. The investment strategy seeks to capitalize on Blackstone's scale and the real-time information provided by its real estate holding to identify and acquire their target investments at attractive pricing.

Shares can be redeemed through a request for repurchase, however, Blackstone limits these redemptions to no more than 2% of Blackstone's NAV per month and no more than 5% of their aggregate value per calendar quarter on the last business day of each calendar month, provided that written notice of redemption is provided five business days prior.

Blackstone PC: This fund's strategy is to invest primarily in originated loans and other securities, including broadly syndicated loans, of United States private companies. The investment strategy seeks to capitalize on Blackstone Credit & Insurance's scale and reputation in the market as an attractive financing partner to acquire target investments at attractive pricing.

Shares can be redeemed through a request for repurchase, however, Blackstone PC limits these redemptions to no more than 5% of Blackstone PC's NAV as of the previous calendar quarter. Blackstone PC reserves the right to amend or suspend the share repurchase program at any time.

Ares: The fund is focused on investing in and operating a diverse portfolio of real property and investment in other real estate-related assets. The objective is to bring Ares leading institutional-quality real estate assets investment platform to income-focused investors, with significant diversification across real estate and real estate-related asset classes, geographies and sectors.

The Corporation can make a request to redeem through a request for repurchase, however, Ares is not obligated to redeem any shares and may choose to redeem only some, or even none, of the shares in any particular month. If Ares approves the redemption, they will only do so on the last day of the calendar month and the redemption is limited to no more than 2% of Ares' NAV per month and no more than 5% of their aggregate value per calendar quarter.

6. Property and Equipment, Net

Property and equipment, net consists of the following at December 31:

	2024			2023
Land and improvements Buildings and improvements Office furniture and equipment Computer software and hardware		45,993 843,267 233,056 141,676	\$	46,015 839,844 207,033 139,680
Total		1,263,992		1,232,572
Less accumulated depreciation		(572,601)		(524,060)
Total		691,391		708,512
Construction in progress		164,006		97,314
Property and equipment, net	\$	855,397	\$	805,826

Depreciation expense on property and equipment was \$48,580 and \$48,116 in 2024 and 2023, respectively, and is included in depreciation and amortization expense in the accompanying consolidated statements of operations. Interest incurred on borrowed funds during the period of construction of capital assets is capitalized as a component of the cost of acquiring those assets. During 2024 and 2023, the Corporation capitalized \$2,650 and \$4,101, respectively, which is net of investment income on assets whose use is limited.

Construction in progress as of December 31, 2024 consists primarily of major renovation and expansion projects of clinical facilities. Purchase commitments related to these and other miscellaneous projects were \$75,304 at December 31, 2024. The cost of these projects is expected to be funded through operations, borrowed funds, as well as transfers from the Corporation's related philanthropy division.

7. Investments and Investments in Unconsolidated Subsidiaries

The Corporation's investments and investments in unconsolidated subsidiaries include the following at December 31, 2024 and 2023:

	2024			
Investment in healthcare entities Investments held by philanthropy	\$	26,910 935	\$	24,123 890
Total	\$	27,845	\$	25,013

Notes to Consolidated Financial Statements December 31, 2024 and 2023 (In Thousands)

Investment in Healthcare Entities

The Corporation has ownership interests in several healthcare entities which are accounted for under the equity method. The Corporation recognized income of \$1,196 and \$2,651 in 2024 and 2023, respectively, related to these investments which is included in other revenues in the accompanying consolidated statements of operations. The investment in healthcare entities is primarily comprised of the following:

The Corporation has a 48.8% ownership interest in White-Oak AHF-1 Manager, LLC (White-Oak) which was organized for the purpose of developing and constructing a medical office building on the White Oak campus of WOMC.

The Corporation holds a 50% ownership interest in Rockville Mid-Atlantic Radiation Oncology, LLC (RMARO) which provides professionally managed radiation management services at SGMC and its surrounding community. The Corporation also has a 50% ownership interest in Mid-Atlantic Radiation Oncology, LLC which provides professionally managed radiation management services at WOMC and the surrounding community.

Adventist HealthCare Surgery Center at National Harbor, LLC (Surgery Center) is an ambulatory surgical facility providing services to patients in the Oxon Hill, MD area. The Corporation has a 35% ownership interest in the Surgery Center.

The Corporation had invested in CoreLife Adventist, LLC (CoreLife) for a 50% interest. The Corporation also had invested in CoreLife Management Services, Inc. (CoreLife Management) for a 15% interest. In May 2023, the Corporation sold its entire membership interest in CoreLife and CoreLife Management to CoreLife Holdings, Inc. The total purchase price of \$4,250 was comprised of two promissory notes of \$2,125, due monthly starting in January 2024 through December 2028. In addition, the Corporation provided a \$900 working capital loan to CoreLife Holdings, Inc., which was due monthly starting January 2024 through December 2025. In conjunction with the sale, the Corporation recorded the notes and derecognized its investment in CoreLife and CoreLife Management. In 2024, the Corporation determined that the promissory notes and the working capital loan were impaired and were written off. The write-off is included in other loss in the accompanying consolidated statements of operations.

Summarized financial information related to these entities is presented below:

		 2023		
Net revenue	\$	23,907	\$ 14,998	
Revenues less than expenses		(1,494)	(1,621)	
Total assets		113,616	114,064	
Total liabilities		88,831	86,197	

The Corporation leases certain building space from related parties. Amounts recorded in the consolidated financial statements related to these leases are as follows for the years ended December 31:

		2023		
Operating lease right-of-use assets Operating lease obligations Lease payments	\$	36,735 38,618 5,110	\$	40,988 42,595 5,002

Notes to Consolidated Financial Statements December 31, 2024 and 2023 (In Thousands)

Investments Held by Philanthropy

Philanthropy also holds marketable debt and equity securities for funds not required to be expended in less than 90 days. These marketable securities are subject to credit and market risks.

8. Land Held for Healthcare Development

From 2002 through 2011, the Corporation acquired various parcels of land in Clarksburg, Maryland totaling approximately 200 acres. Several parcels of the land are fully owned by the Corporation, and the remainder is owned by Cabin Branch Commons, LLC (Cabin Branch), of which the Corporation owns a 45% interest. The Corporation sold approximately 129 acres of the land between 2013 and 2022 and total proceeds received through December 31, 2024 is \$51,242. No gain or loss was recognized on the sale as of December 31, 2024 and 2023. The total remaining land held for healthcare development in Clarksburg as of December 31, 2024 and 2023, was \$2,714 and \$4,061, respectively.

In January 2022, the Corporation entered into a purchase and sale agreement with an unrelated third party to purchase 44.06 acres of land located in Fort Washington, Maryland. The Corporation closed on the purchase of the land in July 2022 at a purchase price of \$3,200. The total value of this land held for healthcare development as of December 31, 2024 and 2023 was \$4,808 and \$4,326, respectively.

9. Short-Term Financing

The Corporation has a \$20,000 unsecured line of credit with a commercial bank, with interest at SOFR plus 1.25% (5.8125% at December 31, 2024). There were no borrowings outstanding under this line of credit as of December 31, 2024 or 2023.

10. Long-Term Obligations

Long-term obligations as of December 31, 2024 and 2023 are comprised of the following:

	2024			2023
Fixed Rate Revenue Bonds Other long-term liabilities	\$	655,459 -	\$	671,118 6,288
Total obligations		655,459		677,406
Plus bond premium Less:		30,890		32,404
Current maturities Deferred financing costs		(16,064) (5,076)		(21,948) (5,363)
Noncurrent portion of long-term obligations, net	\$	665,209	\$	682,499

Notes to Consolidated Financial Statements December 31, 2024 and 2023 (In Thousands)

Fixed Rate Revenue Bonds

Fixed Rate Revenue Bonds consist of the Maryland Health and Higher Educational Facilities Authority Refunding Revenue Bonds. Fixed Rate Revenue Bonds consist of the following at December 31:

	Pa	r Amounts	Maturity Date	Interest Rates	 2024	 2023
Adventist HealthCare, Inc.						
Series 2013	\$	15,623	January 2025	3.21%	\$ 1,594	\$ 3,118
Series 2016A		269,750	January 2046	5.25%-5.50%	259,680	261,135
Series 2016B		126,395	January 2046	3.72%	114,080	116,140
Series 2017		40,000	December 2042	2.77%	32,365	33,735
Series 2020		18,725	January 2038	4.00%	15,315	16,130
Series 2021A		48,120	January 2036	5.00%	36,445	39,695
Series 2021B		138,660	January 2051	4.00%-5.00%	138,660	138,660
Series 2021C		69,835	January 2043	1.23%-3.76%	 57,320	 62,505
Total					\$ 655,459	\$ 671,118

The above bond issues are subject to trust indentures which impose various covenants on SGMC, WOMC, Rehab, Imaging, PE, Other Health Services, Support Center and Philanthropy (collectively, the Obligated Group) which include restrictions on the transfer or disposition of property, the incurrence of additional liabilities and the achievement of certain pre-established financial indicators. Management believes it has complied with these required financial covenants for the years ended December 31, 2024 and 2023. Debt service reserve funds are required on the Series 2016A Bonds.

Mortgage Loan Payable

FWMC had a taxable mortgage loan insured by HUD through the Federal Housing Administration. The loan provided for the satisfaction of FWMC's previous bond obligation and for construction, new equipment and financing costs. In December 2023, the Corporation repaid the loan in full to HUD on behalf of FWMC. In February 2024, the Corporation received notice of legal release of the HUD regulatory agreement.

Notes to Consolidated Financial Statements December 31, 2024 and 2023 (In Thousands)

Other Long-Term Liabilities

The Corporation guaranteed a line of credit, issued by PNC Bank, for one of its investments in unconsolidated subsidiaries, CoreLife Management. The line of credit had a maximum amount of \$6,500 and interest at 9.0%. During 2023, the Corporation received notice that CoreLife Management was in default under the terms of the loan agreement. As a result, the Corporation recorded a liability for the outstanding amount of \$6,288, which reflected the outstanding principal, interest and fees due as of December 31, 2023. This was included in current maturities of long-term obligations on the consolidated balance sheets and the corresponding credit loss was included in other loss on the consolidated statements of operations for the year ended December 31, 2023. In March 2024, the Corporation fully repaid the note in the amount of \$6,233, which reflected the outstanding principal and interest as of the payoff date.

Scheduled principal repayments of long-term obligations, excluding finance and operating lease obligations at December 31, 2024 are as follows:

Years ending December 31:	
2025	\$ 16,064
2026	16,645
2027	17,305
2028	18,025
2029	18,795
Thereafter	 568,625
Total	\$ 655,459

11. Leases

The Corporation leases office space and equipment used in operations. For many of these leases, the Corporation is responsible for paying property taxes, insurance, as well as maintenance and repair costs. The Corporation's real estate leases generally have initial lease terms of three to 20 years or more and typically include one or more options to renew, with renewal terms that generally extend the lease term for an additional five to 10 years or more. The Corporation assesses renewal options using a "reasonably certain" threshold, which is understood to be a high threshold, and therefore, the majority of its leases' terms do not include renewal periods for accounting purposes. The Corporation does not separate lease and non-lease components for all real property asset classes. For leases where the Corporation is reasonably certain to exercise its renewal option, the option periods are included within the lease term, and therefore, the measurement of the right-of-use asset and lease liability. The payment structure of the Corporation's leases generally include annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets, while expenses for these leases are recognized on a straight-line basis over the lease term as an operating expense.

Certain leases include an option to purchase the leased assets. The Corporation assesses the likelihood of exercising the purchase option using a "reasonably certain" threshold, which is understood to be a high threshold, and therefore, purchase options are generally accounted for when a compelling economic reason to exercise the option exists. Certain leases include an option to terminate the lease, the terms and condition of which vary by contract. These options allow the parties to the contract to terminate their obligations typically in return for an agreed-upon financial consideration amount. The Corporation's lease agreements do not contain material residual value guarantees.

Notes to Consolidated Financial Statements December 31, 2024 and 2023 (In Thousands)

The Corporation makes certain assumptions and judgements in determining the discount rate, as most leases do not provide an implicit rate. The Corporation uses a risk-free discount rate based on information available at the commencement date in determining the present value of lease payments. In order to apply the discount rate, a portfolio approach was utilized to group assets based on similar lease terms in a manner whereby the Corporation reasonably expects that the application does not differ materially from application to individual leases.

Subsequent to the lease commencement date, the Corporation reassesses lease classification when there is a contract modification that is accounted for as a separate contract, a change in the lease term or a change in the assessment of whether the lessee is reasonably certain to exercise an option to purchase the underlying asset or terminate the lease.

Future minimum payments under finance lease obligations as of December 31, 2024 were as follows:

Years ending December 31:	
2025	\$ 4,249
2026	4,249
2027	4,249
2028	2,421
2029	206
Thereafter	 -
Total	15,374
Less amount representing interest	 (798)
Total finance lease obligations	14,576
Less current portion	 (3,878)
Long-term obligations	\$ 10,698

Future minimum payments under operating lease obligations as of December 31, 2024 were as follows:

Years ending December 31:	
2025	\$ 15,568
2026	14,640
2027	12,892
2028	10,148
2029	8,532
Thereafter	 41,916
Total	103,696
Less amount representing interest	 (13,982)
Total operating lease obligations	89,714
Less current portion	 (12,878)
Long-term obligations	\$ 76,836

Notes to Consolidated Financial Statements December 31, 2024 and 2023 (In Thousands)

Total lease costs are comprised of the following for the years ended December 31:

		 2023	
Finance lease cost: Amortization of right-of-use asset Interest on lease obligations Operating lease cost	\$	4,037 484 16,440	\$ 4,059 596 18,563
Total lease cost	\$	20,961	\$ 23,218

Other supplemental information as of and for the years ended December 31, 2024 and 2023 is as follows:

	2024	2023
Weighted-average remaining lease term: Finance lease obligations	3.68 years	4.66 years
Operating lease obligations	8.71 years	9.33 years
Weighted-average discount rate: Finance lease obligations	2.98 %	2.97 %
Operating lease obligations	3.52 %	3.29 %

Certain lease agreements contain a number of restrictive covenants that, among other things, are subject to certain exemptions, impose operating and financial restrictions on the Corporation.

12. Retirement, Health Plan and Life Insurance

Defined Contribution Retirement Plan

The Corporation sponsors a 401(a) defined contribution retirement plan, which covers substantially all full-time employees. After 12 months of full-time or regular part-time employment of at least 1,000 base hours, the Corporation will contribute a total of 2% of eligible employees' compensation, plus a matching employer contribution equal to 50% of employee contributions (to the 403(b) plan) up to 6% of base salary. The Corporation also has a 403(b) retirement savings plan for employees. Employee contributions are made to the 403(b) retirement savings plan. Retirement plan expense was \$15,732 and \$14,516 in 2024 and 2023, respectively.

Supplemental Executive Retirement Plan

The Corporation also has a Supplemental Executive Retirement Plan (SERP) that became effective in 2015 and covers a group of key executives. SERP expense was \$71 in 2023. There was no SERP expense in 2024. In addition, a SERP adjustment was recorded to increase the liability for \$20 in 2024 and to decrease the liability for \$557 in 2023, which was recognized in net assets without donor restrictions in the consolidated statements of changes in net assets. At December 31, 2024 and 2023, the Corporation's liability for the SERP was \$95 and \$1,433, respectively, which is included in other liabilities in the consolidated balance sheets.

Notes to Consolidated Financial Statements December 31, 2024 and 2023 (In Thousands)

Executive Retention 457(F) Plan

Effective January 1, 2015, the Corporation established the Executive Retention 457(F) Plan (the 457(F) Plan). The 457(F) Plan is a tax-deferred plan offered to key executives, whereby annual employer contributions are made to the Plan. Plan participants become vested in the contributions and receive plan payments in the second calendar year after the contribution is made, if the participant is still employed. The final contribution will be made to the Plan for the year in which the plan participant becomes 62. The 457(F) Plan expense was \$1,858 in 2024 and \$2,963 in 2023. The Corporation's liability for the 457(F) Plan at December 31, 2024 and 2023 was \$4,586 and \$4,935, respectively, which is included in other liabilities in the consolidated balance sheets.

Salary Deferral (457(b)) Plan

Employees who contribute the maximum allowable amount to the 403(b) retirement plan have an opportunity to contribute additional funds on a tax-deferred basis to a 457(b) retirement plan up to the maximum tax-sheltered opportunity. There are no employer contributions to this plan.

Health Plan

The Corporation maintains a self-insurance employee program for its health insurance coverage. The Corporation accrues the estimated costs of incurred and reported and incurred but not reported claims, after consideration of its stop-loss insurance coverage, based upon data provided by the third-party administrator of the program and historical claims experience.

Life Insurance

Full-time and part-time employees are insured, through a third-party carrier, for an amount equal to one times their base salary at time of enrollment up to \$450 for full-time employees and \$10 for part-time employees. In addition, if death is caused by accident, the employee is insured for an additional benefit equal to the amount of their life insurance.

13. Commitments and Contingencies

Litigation and Claims

The Corporation is subject to asserted and unasserted claims (in addition to litigation) encountered in the ordinary course of business. In the opinion of management and after consultation with legal counsel, the Corporation has established adequate reserves related to all known matters. The outcome of any potential investigative, regulatory or prosecutorial activity that may occur in the future cannot be predicted with certainty. However, any associated potential future losses resulting from such activity could have a material adverse effect on the Corporation's future financial position, results of operations and liquidity.

Insurance

The Corporation's primary coverage for professional liability is provided through a self-funded insurance retention fund (the Fund) established on January 1, 1993, which is funded based on actuarial estimates and provides coverage of \$5,000 per occurrence with no annual aggregate limitation. The Fund also provides general liability coverage up to \$1,000 per occurrence and \$3,000 in the aggregate. The Corporation also carries umbrella excess liability insurance on a claims made basis with a commercial carrier, with stacked limits of \$10,000 per occurrence and in aggregate, for a total of \$20,000 per occurrence and in aggregate.

Notes to Consolidated Financial Statements December 31, 2024 and 2023 (In Thousands)

It is the Corporation's policy to accrue for the ultimate cost of uninsured asserted and unasserted malpractice claims, if any, when incidents occur. Based on a review of the Corporation's prior experience and incidents occurring through December 31, 2024, management determined that the fully-funded professional liability reserve reported at December 31, 2024 and 2023 is adequate in light of the program's excess umbrella policy currently in force and historical claims experience. The estimated professional liability for both asserted and unasserted claims was \$11,821 and \$14,494 at December 31, 2024 and 2023, respectively. The discount rate used in determining these liabilities was 2.5% at both December 31, 2024 and 2023.

The Corporation is self-insured for unemployment and workers' compensation benefits. The liability for unemployment and workers' compensation claims payable is an estimate based on the Corporation's past experience and is included in other liabilities in the accompanying consolidated balance sheets. It is reasonably possible that the estimates used could change materially in the near term.

Defined Benefit Plan - Multiemployer Plan

Prior to January 1, 1992, the Corporation participated in a multiemployer, noncontributory, defined benefit retirement plan, the Seventh-day Adventist Hospital Retirement Plan Trust (Old Plan) sponsored and administered by the North American Division of the General Conference of Seventh-day Adventists that is exempt from ERISA. The employer identification number of the Old Plan is 52-2000393. The risks of participating in multiemployer plans are different from single employer plans in that: (a) assets contributed to the multiemployer plan by one employer may be used to provide benefits to employees of other participating employers; (b) if a participating employer stops contributing to the plan, the unfunded obligations of the plan may be borne by the remaining participating employers; and (c) if an entity chooses to stop participating in the multiemployer plan, it may be required to pay the plan an amount based on the underfunded status of the plan, referred to as withdrawal liability.

During 1992, the Old Plan was frozen and the Corporation, along with the other participants in the Old Plan, may be required to make future contributions to the Old Plan to fund any difference between the present value of the Old Plan benefits and the fair value of the Old Plan assets. During 2024, the administrators of the Old Plan notified the Corporation of a required contribution. The Corporation contributed \$2,956 (8.5% of the total required contributions to the Old Plan) to the Old Plan in July 2024, which is included in other loss in the accompanying consolidated statements of operations. The Corporation was not required to and did not make any contributions to the Old Plan for the year ended December 31, 2023. Management believes the impact of any such future funding requirements will not have a material adverse effect on the Corporation's consolidated financial statements.

The most recently available plan assets and actuarially determined benefit obligation for the Old Plan, which includes all participating employers as of January 1, 2024 is as follows:

Total plan assets	\$ 328,334
Actuarial present value of accumulated plan benefits	
(unaudited)	688,585
Funded status (unaudited)	48%

14. Business and Credit Concentrations

The Corporation grants credit to patients, substantially all of whom are local residents. The Corporation generally does not require collateral or other security in extending credit, however, it routinely obtains assignment of (or is otherwise entitled to receive) patients' benefits receivable under their health insurance programs, plans or policies.

At December 31, 2024 and 2023, concentrations of gross receivables from third-party payors and others are as follows:

	2024	2023
Medicare	15 %	16 %
Medicaid	9	12
Other third-party payors	57	53
Self-pay and others	19	19
	100 %	100 %

The Corporation maintains its cash and cash equivalents with several financial institutions. Cash and cash equivalents on deposit with any one financial institution are insured up to \$250.

15. Liquidity and Availability

The Corporation's financial assets available for general expenditures within one year of the consolidated balance sheets date, consist of the following at December 31:

	 2024	 2023
Cash and cash equivalents Short-term investments Patient accounts receivable Other receivables Assets whose use is limited,	\$ 35,051 276,816 131,482 16,835	\$ 30,207 292,515 137,907 16,793
Professional liability fund	 14,546	 15,410
Total	\$ 474,730	\$ 492,832

The Corporation has designated certain assets as available for settling professional liability claims, however, these assets could be used for general expenditures if necessary, and therefore, have been included in the information above.

As part of the Corporation's liquidity management plan, it has a policy to structure its financial assets to be available as its general expenditures, liabilities and other obligations come due. In addition, the Corporation invests excess cash in short-term investments.

Notes to Consolidated Financial Statements December 31, 2024 and 2023 (In Thousands)

16. Functional Expenses

A summary of the Corporation's operating expenses by function for the year ended December 31, 2024 is as follows:

	A Ai	Hospital Acute and mbulatory Services	Home Care Services		Other Health Care Services		Other, Including General and Administrative		Including General and		 Total		
Salaries and wages	\$	321,091	\$	14,674	\$	118,960	\$	60,490	\$	1,575	\$ 516,790		
Employee benefits		61,150		2,835		19,592		7,062		370	91,009		
Contract labor		49,032		638		3,698		1,308		10	54,686		
Medical supplies		113,627		306		8,392		54		3	122,382		
General and administrative		62,342		3,591		21,239		45,797		797	133,766		
Building and maintenance		40,170		653		13,121		1,260		2	55,206		
Insurance		6,531		167		2,121		928		-	9,747		
Interest Depreciation and		19,835		1		1,467		2,421		-	23,724		
amortization		38,483		100	5,110			8,918		8,918		6	 52,617
Total	\$	712,261	\$	22,965	\$	193,700	\$	128,238	\$	2,763	\$ 1,059,927		

In 2024, the Corporation also incurred other health care services expenses of \$1,219 related to the Takoma Park campus that were included in the loss from discontinued operations in the consolidated statements of operations. These expenses were comprised of miscellaneous other operating expenses related to the maintenance of the Takoma Park Campus.

A summary of the Corporation's operating expenses by function for the year ended December 31, 2023 is as follows:

	A	Hospital Acute and mbulatory Services	Home Care Services		Other Health Care Services		Other, Including General and Administrative		Fundraising		 Total
Salaries and wages	\$	301,499	\$	13,914	\$	115,840	\$	55,869	\$	1,281	\$ 488,403
Employee benefits		58,238		2,773		19,006		11,101		356	91,474
Contract labor		58,580		452		26,170		1,505		30	86,737
Medical supplies		112,717		299		9,416		(95)		-	122,337
General and administrative		65,774		3,210		24,327		39,475		365	133,151
Building and maintenance		43,568		775		13,145		1,838		2	59,328
Insurance		6,385		166		2,288		(689)		-	8,150
Interest		20,366		1		1,522		2,348		-	24,237
Depreciation and amortization		38,384		95		5,579		8,934		8	 53,000
Total	\$	705,511	\$	21,685	\$	217,293	\$	120,286	\$	2,042	\$ 1,066,817

In 2023, the Corporation also incurred other health care services expenses of \$2,178 related to the Takoma Park campus that were included in the loss from discontinued operations in the consolidated statements of operations. These expenses were comprised of miscellaneous other operating expenses related to the operations of the walk-in clinic.

	Shady Grove Medical Center	White Oak Medical Center	Rehab	Imaging	Adventist HealthCare Physician Enterprise	Other Health Services	Support Center	Philanthropy	Eliminating Entries	Total Combined Obligated Group
Assets										
Current Assets										
Cash and cash equivalents	\$ 319,889	\$ (145,432)	\$ 27,704	\$ (27,870)	\$ (75,617)		\$ (89,366)	\$ 9,506	\$ -	\$ 46,902
Short-term investments Assets whose use is limited	- 6,935	- 8,431	-	-	-	- 1,598	276,816 10,179	-	-	276,816 27,143
Patient accounts receivable	6,935 66,301	8,431 36,012	- 7,579	- 3,419	- 1,901	1,598 (5)	10,179	-	-	27,143
Other receivables	1,597	2,624	544	3,419 11	240	(5)	7,030	- 2,444	(1,645)	13,396
Inventories	4,807	5,276	124	-	-	148	-	-	(1,040)	10,355
Prepaid expenses and other current assets	2,690	2,761	134	127	199	430	11,373	-	-	17,714
		·					· · · · · ·			· · · · · ·
Total current assets	402,219	(90,328)	36,085	(24,313)	(73,277)	30,810	216,457	11,950	(1,645)	507,958
Property and Equipment, Net	305,241	417,138	18,731	7,807	2,740	563	70,188	-	-	822,408
Finance Lease Right-of-Use Assets	6,949	1,784	574	2,719	43	147	1,640	-	-	13,856
Operating Lease Right-of-Use Assets	12,682	25,015	6,344	4,304	7,215	1,781	88	-	-	57,429
Assets Whose Use is Limited										
Under trust indentures, held by trustees and banks	51,437	21,258	478	-	-	-	4,486	-	-	77,659
Professional liability fund	-	-	-	-	-	-	11,297	-	-	11,297
Deferred compensation fund	-	-	-	-	-	-	2,863	-	-	2,863
Cash and Cash Equivalents Restricted for Capital Acquisitions	-	-	271	-	-	-	-	6	-	277
Investments and Investments in Unconsolidated Subsidiaries	3,225	13,853	-	-	-	-	27,955	935	-	45,968
Land Held for Healthcare Development	-	-	-	-	-	-	7,522	-	-	7,522
Intangible Assets, Net	435	-	620	5,435	-	-	-	-	-	6,490
Deposits and Other Noncurrent Assets	40	34	85	51	18	33	7,229	1,844	-	9,334
Assets Held for Sale						14,814				14,814
Total assets	\$ 782,228	\$ 388,754	\$ 63,188	\$ (3,997)	\$ (63,261)	\$ 48,148	\$ 349,725	\$ 14,735	\$ (1,645)	\$ 1,577,875

	Fort Washington Medical Center		n Lourie Center		Adventist Home Care Services		Other Leasehold Services		Adventist HealthCare Physician Alliance		Eliminating Entries	Consolidated Adventist HealthCare, Inc.	
Assets													
Current Assets													
Cash and cash equivalents	\$	(8,714)	\$	(1,107)	\$	13,619	\$	(12,442)	\$	(3,207)	\$-	\$	35,051
Short-term investments		-		-		-		-		-	-		276,816
Assets whose use is limited		-		-		-		-		-	-		27,143
Patient accounts receivable Other receivables		12,053		161		3,636		- 3		-	-		131,482
Inventories		1,116 614		2,325		(5)		3		-	-		16,835 10,969
Prepaid expenses and other current assets		296		- 5		- 31		- 45		- 51	-		18,142
riepaid expenses and other current assets		290		5		51		45		51			10,142
Total current assets		5,365		1,384		17,281		(12,394)		(3,156)	-		516,438
Property and Equipment, Net		30,546		580		443		1,420		-	-		855,397
Finance Lease Right-of-Use Assets		-		-		18		-		-	-		13,874
Operating Lease Right-of-Use Assets		17,568		2,085		2,711		4,535		-	-		84,328
Assets Whose Use is Limited													
Under trust indentures, held by trustees and banks		-		-		-		-		-	-		77,659
Professional liability fund		-		-		-		-		-	-		11,297
Deferred compensation fund		-		-		-		-		-	-		2,863
Cash and Cash Equivalents Restricted for Capital Acquisitions		6		428		-		-		-	-		711
Investments and Investments in Unconsolidated Subsidiaries		-		-		-		-		-	(18,123)		27,845
Land Held for Healthcare Development		-		-		-		-		-	-		7,522
Intangible Assets, Net		-		-		84		-		-	-		6,574
Deposits and Other Noncurrent Assets		37		-		27		63		-	-		9,461
Assets Held for Sale		-		-				-		-			14,814
Total assets	\$	53,522	\$	4,477	\$	20,564	\$	(6,376)	\$	(3,156)	\$ (18,123)	\$	1,628,783

	Shady Grove Medical Center	White Oak Medical Center	Rehab	Imaging	Adventist HealthCare Physician Enterprise	Other Health Services	Support Center	Philanthropy	Eliminating Entries	Total Combined Obligated Group
Liabilities and Net Assets (Deficit)										
Current Liabilities										
Accounts payable and accrued expenses	\$ 46,104	\$ 22,988	\$ 2,900	\$ 665	\$ 1,601	\$ 490	\$ 22,344	\$ (23)	\$-	\$ 97,069
Accrued compensation and related items	16,173	10,308	3,947	1,614	2,225	323	22,597	-	(1,645)	55,542
Interest payable		-	-	-	-	-	9,600	-	-	9,600
Deferred revenues	5,624	259	12	-	106	100	31	-	-	6,132
Due to third-party payors	11,859	10,766	(783)	-	43	-	(112)	-	-	21,773
Estimated self-insured professional liability Current maturities of:	-	-	-	-	-	-	3,249	-	-	3,249
Long-term obligations	- 3,392	- 4,974	- 522	-		- 1,594	- 5,039	-	-	- 15,521
Finance lease obligations	1,988	4,974	170	- 724	- 14	43	450	-	-	3,872
Operating lease obligations	3,997	2,675	622	1,448	1,020	43 195	430 28	-	-	9,985
Operating lease obligations	5,551	2,013	022	1,440	1,020	100				3,303
Total current liabilities	89,137	52,453	7,390	4,451	5,009	2,745	63,226	(23)	(1,645)	222,743
Construction Payable	10,711	3,477	8	-	-	2,760	-	-	-	16,956
Long-Term Obligations, Net										
Bonds payable	261,410	336,914	2,878	-	-	-	64,007	-	-	665,209
Notes payable	-	-	-	-	-	-	(1,860)	-	-	(1,860)
Finance Lease Obligations	5,320	1,385	436	2,136	31	110	1,265	-	-	10,683
Operating Lease Obligations	9,440	23,182	6,031	3,216	6,527	1,740	60	-	-	50,196
Other Liabilities	770	29	5	-	253	-	13,424	43	-	14,524
Estimated Self-Insured Professional Liability	-	-	-	-	-	-	8,572	-	-	8,572
Total liabilities	376,788	417,440	16,748	9,803	11,820	7,355	148,694	20	(1,645)	987,023
Total habilities	3/0,/00	417,440	10,740	9,803	11,620	7,355	146,094	20	(1,045)	987,023
Net Assets (Deficit)										
Net assets (deficit) without donor restrictions	405,436	(28,739)	45,443	(13,800)	(75,081)	40,793	200,573	3,837	-	578,462
Net assets with donor restrictions	400,400	(20,700)	997	(.0,000)	(. 0,001)		458	10,878	-	12,390
	· · ·		501				100		-	,
Total net assets (deficit)	405,440	(28,686)	46,440	(13,800)	(75,081)	40,793	201,031	14,715		590,852
Total liabilities and net assets (deficit)	\$ 782,228	\$ 388,754	\$ 63,188	\$ (3,997)	\$ (63,261)	\$ 48,148	\$ 349,725	\$ 14,735	\$ (1,645)	\$ 1,577,875

		Fort Washington Medical Center		Lourie Center		Adventist Home Care Services		Other Leasehold Services		Adventist HealthCare Physician Alliance		Eliminating Entries		solidated Iventist althCare, Inc.
Liabilities and Net Assets (Deficit)														
Current Liabilities														
Accounts payable and accrued expenses	\$	18,568	\$	207	\$	236	\$	133	\$	668	\$	-	\$	116,881
Accrued compensation and related items		2,153		668		1,312		-		110		-		59,785
Interest payable		-		-		-		-		-		-		9,600
Deferred revenues		-		1,154		-		-		656		-		7,942
Due to third-party payors		447		-		-		-		-		-		22,220
Estimated self-insured professional liability		-		-		-		-		-		-		3,249
Current maturities of:		-		-		-		-		-		-		-
Long-term obligations		543		-		-		-		-		-		16,064
Finance lease obligations		-		-		6		-		-		-		3,878
Operating lease obligations		1,313		551		301		728		-		-		12,878
Total current liabilities		23,024		2,580		1,855		861		1,434		-		252,497
Construction Payable		24		-		-		-		-		-		16,980
.ong-Term Obligations, Net														
Bonds payable		-		-		-		-		-		-		665,209
Notes payable		1,860		-		-		-		-		-		· -
		,												
inance Lease Obligations		-		-		15		-		-		-		10,698
Operating Lease Obligations		18,307		1,581		2,657		4,095		-		-		76,836
ther Liabilities		-		-		-		-		-		-		14,524
stimated Self-Insured Professional Liability														8,572
Total liabilities		43,215		4,161		4,527		4,956		1,434		-		1,045,316
let Assets (Deficit)														
Net assets (deficit) without donor restrictions		9,970		(37)		16,029		(11,332)		(4,590)		(18,016)		570,486
Net assets with donor restrictions		3,370		353		8		(11,002)		(4,000)		(10,010) (107)		12,981
		551		000		0		-				(107)		12,001
Total net assets (deficit)		10,307		316		16,037		(11,332)		(4,590)		(18,123)		583,467
i utai net assets (denut)		10,307		310		10,037		(11,332)		(4,090)		(10,123)		505,407
Total liabilities and net assets (deficit)	\$	53,522	\$	4,477	\$	20,564	\$	(6,376)	\$	(3,156)	\$	(18,123)	\$	1,628,783

Adventist HealthCare, Inc. and Controlled Entities Consolidating Schedule, Statement of Operations Year Ended December 31, 2024 (In Thousands)

	Shady Grove Medical Center	White Oak Medical Center	Rehab	Imaging	Adventist HealthCare Physician Enterprise	Other Health Services	Support Center	Philanthropy	Eliminating Entries	Total Combined Obligated Group
Revenues	• • • • • • • • • •	• • • • • • • • • •	A 77 000	A A A A A A A A A A	a a a a a a a a a a	<u>^</u>	•	•	•	A 000 00 (
Net patient service revenue Other revenues COVID-19 grant income	\$ 470,148 12,692 -	\$ 320,902 8,531 -	\$ 77,328 242 -	\$ 35,704 1,392 -	\$ 29,122 2,028 -	\$- 7,604 -	\$- 8,013 4,117	\$- 1,806 -	\$- (10,262) -	\$ 933,204 32,046 4,117
Total revenues	482,840	329,433	77,570	37,096	31,150	7,604	12,130	1,806	(10,262)	969,367
Expenses										
Salaries and wages	192,318	120,141	42,037	20,557	24,835	3,312	61,609	-	(90)	464,719
Employee benefits	36,742	22,034	8,074	2,580	3,789	631	7,324	-	(13)	81,161
Contract labor	22,891	22,152	1,285	(2,839)	(565)	(265)	1,308	-	-	43,967
Medical supplies	60,997	47,754	2,388	3,297	1,326	873	57	-	(5)	116,687
General and administrative Building and maintenance	34,542 23,146	28,285 13,185	7,068 4,746	2,664 5,163	4,922 2,812	1,643 757	46,034 1,261	2,539	(7,291)	120,406 48,207
5	3,724	2,880	4,746	489	572	6	928	-	(2,863)	48,207 9,018
Insurance Interest	3,724 4,444	2,000 15,391	128	489	572	1,238	928 2,421	-	-	23,723
Depreciation and amortization	16.631	19,624	2,110	2.048	437	91	8.920			49.861
IT depreciation	5,630	2,648	412	2,040		24	(8,969)	-	-	(179)
IT services	21,458	11,653	2,108	1,177	119	131	(37,785)			(1,139)
Shared services	24,605	14,749	2,051	633	944	95	(47,416)	-	-	(4,339)
Management fees	9,942	5,716	1,417	494	493	146	(19,979)	-	-	(1,771)
Total expenses	457,070	326,212	74,243	36,439	39,685	8,682	15,713	2,539	(10,262)	950,321
Income (loss) from operations	25,770	3,221	3,327	657	(8,535)	(1,078)	(3,583)	(733)		19,046
Other Income (Expense)										
Investment income	6,970	566	557	-	-	53	6,310	61	-	14,517
Other loss	-	-	-	-	-	-	(9,393)	-	-	(9,393)
Total other income (expense)	6,970	566	557			53	(3,083)	61		5,124
Revenues in excess of (less than) expenses from continuing operations	32,740	3,787	3,884	657	(8,535)	(1,025)	(6,666)	(672)	-	24,170
Change in Net Unrealized Gains on Investments in Debt Securities	5,176	332	312	-	-	32	2,595	3	-	8,450
Transfer of Net Assets	-	-	-	-	-	(165)	165	-	-	-
Net Assets Released From Restrictions for Purchases of Property and Equipment	72	565	54	-	-	-	-	(50)	-	641
Deferred Compensation Plan Liability Adjustment	-	-	-	-	-	-	(20)	-	-	(20)
Other Net Asset Activity			(4)				701			697
Increase (decrease) in net assets (deficit) without donor restrictions from continuing operations	37,988	4,684	4,246	657	(8,535)	(1,158)	(3,225)	(719)	-	33,938
Loss From Discontinued Operations						(1,219)				(1,219)
Increase (decrease) in net assets (deficit) without donor restrictions	\$ 37,988	\$ 4,684	\$ 4,246	\$ 657	\$ (8,535)	\$ (2,377)	\$ (3,225)	\$ (719)	<u>\$-</u>	\$ 32,719

Adventist HealthCare, Inc. and Controlled Entities Consolidating Schedule, Statement of Operations Year Ended December 31, 2024 (In Thousands)

	Wash Mee	Fort Washington Medical Lourie Center Center		Adventist Home Care Services		Other Leasehold Services		Adventist HealthCare Physician Alliance		Eliminating Entries		Consolidated Adventist HealthCare, Inc.		
Revenues														
Net patient service revenue	\$	59,312	\$	1,259	\$	25,450	\$	3	\$	589	\$	-	\$	1,019,817
Other revenues		1,494		16,024		85		281		7,432		(3,953)		53,409
COVID-19 grant income		-		-		-		-		-		-		4,117
Total revenues		60,806		17,283		25,535		284		8,021		(3,953)		1,077,343
Expenses														
Salaries and wages		26,581		9,191		14,674		-		2,061		(436)		516,790
Employee benefits		4,659		1,969		2,835		-		397		(12)		91,009
Contract labor		7,247		212		638		-		3,412		(790)		54,686
Medical supplies		5,070		294		306		- 22		25		-		122,382
General and administrative Building and maintenance		6,901 4,765		4,424 716		3,646 653		22 1,053		814		(2,447) (188)		133,766 55,206
Insurance		4,705		26		167		1,055		-		(100)		9,747
Interest		107		- 20		107		_		_		(107)		23,724
Depreciation and amortization		2,350		141		100		165		-		-		52,617
IT depreciation		112		-		67		-		-		-		-
IT services		445		-		694		-		-		-		-
Shared services		3,418		389		532		-		-		-		-
Management fees		551		345		875		-		-		-		-
Total expenses		62,742		17,707		25,188		1,240		6,709		(3,980)		1,059,927
Income (loss) from operations		(1,936)		(424)		347		(956)		1,312		27		17,416
Other Income (Expense)														
Investment income		-		11		301		-		-		-		14,829
Other loss		-		-		-		-		-		-		(9,393)
Total other income (expense)		-		11		301		-		-				5,436
Revenues in excess of (less than) expenses from continuing operations		(1,936)		(413)		648		(956)		1,312		27		22,852
Change in Net Unrealized Gains on Investments in Debt Securities		-		-		184		-		-		-		8,634
Transfer of Net Assets		-		-		-		-		-		-		-
Net Assets Released From Restrictions for Purchases of														
Property and Equipment		58		-		-		-		-		-		699
Deferred Compensation Plan Liability Adjustment		-		-		-		-		-		-		(20)
Other Net Asset Activity		-		-		-		-		-		-		697
Increase (decrease) in net assets (deficit) without donor restrictions from continuing operations		(1,878)		(413)		832		(956)		1,312		27		32,862
Loss From Discontinued Operations		-				-		-				-		(1,219)
Increase (decrease) in net assets (deficit) without donor restrictions	\$	(1,878)	\$	(413)	\$	832	\$	(956)	\$	1,312	\$	27	\$	31,643

43